Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seagen Inc. - Common Stock (NQ:SGEN)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 13, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
BioNTech Stock Surges On Surprise Profit, Strong Sales. But Report Has Downside. ↗
The company was expected to report a third-quarter loss and plummeting sales. 
Via Investor's Business Daily
News headline image
This Is The 'Only Solar Stock' Jim Cramer Is Recommending 'Because It's A Pure Play' ↗
On CNBC’s "Mad Money Lightning Round," Jim Cramer said DocuSign, Inc. 
Via Benzinga
News headline image
CPRI, SGEN, VMW: Why These 3 Stocks Are on the Tip of Bill Gross’ Tongue ↗
Bill Gross, the Bond King, is wading into the world of equity arbitrage with these three stocks - but are they worth the risk for investors? 
Via InvestorPlace
News headline image
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Seagen Highlights First Solid Tumor Data for an ADCETRIS® (brentuximab vedotin) Immunotherapy Combination and Preclinical Data for Novel CD30-Directed Antibody-Drug Conjugate at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Seagen Inc.
Via Business Wire
News headline image
This High-Yield Dividend Stock Is a Proven Wealth Creator ↗
This heavily sold-off pharma stock is a bargain. 
Via The Motley Fool
News headline image
Looking At Seagen's Recent Unusual Options Activity ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
New Data for ADCETRIS® (brentuximab vedotin) with Immunotherapy Combination in Hodgkin Lymphoma to be Featured at 2023 ASH Annual Meeting, and Seagen to Unveil Novel CD30-Directed Antibody-Drug Conjugate
From Seagen Inc.
Via Business Wire
News headline image
Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress
From Seagen Inc.
Via Business Wire
News headline image
The 7 Most Undervalued Long-Term Stocks to Buy: October 2023 ↗
Equities remain under pressure, but if you’re looking to be a contrarian investor, it’s a good time to look for undervalued long-term stocks. 
Via InvestorPlace
News headline image
(SGEN) - Analyzing Seagen's Short Interest ↗
 
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Climbs to New 52-Week High
Via Investor Brand Network
News headline image
Earnings Scheduled For November 1, 2023 ↗
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion. 
Via Benzinga
News headline image
Earnings Outlook For Seagen ↗
 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
Seagen Inc. (NASDAQ: SGEN) Sets New 52-Week High in Tuesday Session
Via Investor Brand Network
News headline image
How This New Merck Regimen Could 'Rewrite Textbooks' In Cancer Treatment — And Bolster 4 Stocks ↗
The companies studied a combination of Keytruda and Padcev in bladder cancer patients. 
Via Investor's Business Daily
News headline image
Groundbreaking EV-302 Trial Significantly Extends Overall Survival and Progression-Free Survival in Patients Treated with PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) in First-Line Advanced Bladder Cancer
From Seagen Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Seagen 5 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Seagen? ↗
 
Via Benzinga
News headline image
TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial
From Seagen Inc.
Via Business Wire
News headline image
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Biotech Companies Make Further Progress in Promising Pancreatic Cancer Treatment Research
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:BNTX),(NASDAQ:SGEN),(NASDAQ:MYGN),(NASDAQ:ILMN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Seagen to Highlight Overall Survival Data for PADCEV® and TIVDAK® during Presidential Symposium at ESMO Congress 2023
From Seagen Inc.
Via Business Wire
News headline image
Seagen to Report Third Quarter 2023 Financial Results on November 1, 2023
From Seagen Inc.
Via Business Wire
Young Adults and Pancreatic Cancer: What the 80% Rise in Diagnoses Means for Future Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GNLX),(NASDAQ:CRNX),(NYSE:PFE),(NASDAQ:SGEN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study ↗
Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual primary endpoints of disease-free survival for the adjuvant... 
Via Benzinga
News headline image
2 High-Yield Dividend Stocks to Buy in October ↗
These two high-yield dividend stocks are too cheap to ignore. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.